Identification of adverse drug reactions that may be related to pharmacogenetics in a public hospital in the South of Brazil

References

• (OPAS/OMS) RPAHRF. Rede Pan-Americana de Harmonização da Regulamentação Farmacêutica. 2011.
   Google Scholar
• Ser WHOTR. International drug monitoring: the role of national centres. Report of a WHO meeting. World Health Organ Tech Rep Ser. 1972;498.
   Google Scholar
• Pinheiro HCG, Pepe VLE. Reações adversas a medicamentos: conhecimento e atitudes dos profissionais de saúde em um hospital-sentinela de ensino do Ceará-Brasil, 2008. Epidemiologia e Serviços de Saúde. 2011;20:57–64.
   Google Scholar
• Khan LM. Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay - A systematic review. Eur J Clin Pharmacol. 2013;69(12):1985–1996.
   PubMed Web of Science ®Google Scholar
• Santos L, Torriani MS, Barros E. Medicamentos na prática da farmácia clínica. 1st Artmed, editor. Porto Alegre; 2013
   Google Scholar
• Rsc D. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events [Internet]. 2017 [cited 2022 Dec 6]. Available from: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf.
   Google Scholar
• Fuchs FD, Wannmacher L. Farmacologia Clínica e Terapêutica. 5th Grupo GEN, editor. São Paulo; 2017
   Google Scholar
• Sousa LAO, De, Fonteles MM, de F, Monteiro MP, et al. Prevalência e características dos eventos adversos a medicamentos no Brasil. Cad Saude Publica. 2018;34. DOI:10.1590/0102-311x00040017.
   Google Scholar
• Plumpton CO, Roberts D, Pirmohamed M, et al. A systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions. Pharmacoeconomics. 2016;34(8):771–793.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Escudero I, Cedeño JA, Rodríguez-Nazario I, et al. Assessment of the clinical utility of pharmacogenetic guidance in a comprehensive medication management service. J Am Collg Clinic Phar 2020;3(6):1028–1037.
   PubMedGoogle Scholar
• Mqp LOPES. Avaliação dos fenótipos de acetilação e hidroxilação predominantes nas populações de cinco macrorregiões do Brasil baseada no genomapossível influência da farmacogenética na conduta terapêutica da hanseníase. Rio de Janeiro; 2015.
   Google Scholar
• Daly AK. Pharmacogenetics: a general review on progress to date. Br Med Bull. 2017;1–15. DOI:10.1093/bmb/ldx035
   Web of Science ®Google Scholar
• de Souza CAC. FARMACOGENÔNIMA: JANELA À MEDICINA PERSONALIZADA. Int J Psych. 2013;18:8.
   Google Scholar
• Yang JQ, Morin S, Verstuyft C, et al. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam Clin Pharmacol. 2003;17(3):373–6.
   PubMed Web of Science ®Google Scholar
• Whirl-Carrillo M, Huddart R, Gong L, et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2021;110:563–572.
   PubMed Web of Science ®Google Scholar
• Ersulo TA, Yizengaw MA, Tesfaye BT. Incidence of adverse drug events in patients hospitalized in the medical wards of a teaching referral hospital in Ethiopia: a prospective observational study. BMC Pharmacol Toxicol. 2022;23:30.
   PubMed Web of Science ®Google Scholar
• Morimoto T, Sakuma M, Matsui K, et al. Incidence of adverse drug events and medication errors in Japan: the JADE study. J Gen Intern Med. 2011;26:148–153.
   PubMed Web of Science ®Google Scholar
• Kiguba R, Karamagi C, Bird SM. Incidence, risk factors and risk prediction of hospital-acquired suspected adverse drug reactions: a prospective cohort of Ugandan inpatients. BMJ Open. 2017;7:e010568.
   PubMed Web of Science ®Google Scholar
• Lobo MGA, de A, Pinheiro SMB, Castro JGD, et al. Adverse drug reaction monitoring: support for pharmacovigilance at a tertiary care hospital in Northern Brazil. BMC Pharmacol Toxicol. 2013;14. doi: 10.1186/2050-6511-14-5.
   PubMed Web of Science ®Google Scholar
• Ribeiro MR. Incidência e fatores de risco de reações adversas a medicamentos em pacientes hospitalizados em clínicas de especialidades do Hospital das Clínicas da FMUSP. São Paulo; 2015.
   Google Scholar
• Moore T, Bennett C. Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the u.s. food and drug administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012;38:905–907.
   PubMed Web of Science ®Google Scholar
• Modesto ACF, Ferreira TXAM, Provin MP, et al. Reações Adversas a Medicamentos e Farmacovigilância: conhecimentos e Condutas de Profissionais de Saúde de um Hospital da Rede Sentinela. Rev Bras Educ Med. 2016;40:401–410.
   Google Scholar
• Cacabelos R, Cacabelos N, Carril JC. The role of pharmacogenomics in adverse drug reactions. Expert Rev Clin Pharmacol. 2019;12(5):407–442.
   PubMed Web of Science ®Google Scholar
• Arwood MJ, Chumnumwat S, Cavallari LH, et al. Implementing Pharmacogenomics at Your Institution: establishment and Overcoming Implementation Challenges. Clin Transl Sci. 2016;9:9.
   PubMed Web of Science ®Google Scholar
• la Russa R, Fineschi V, Di Sanzo M, et al. Personalized medicine and adverse drug reactions: the experience of an Italian teaching hospital. Curr Pharm Biotechnol. 2017;18:274–281.
   PubMed Web of Science ®Google Scholar
• Minard-Colin V, Aupérin A, Pillon M, et al. Rituximab for high-risk, mature b-cell non-hodgkin’s lymphoma in children. N Engl J Med. 2020;382:2207–2219.
   PubMed Web of Science ®Google Scholar
• Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J. 2017;17:395–402.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116:496–526.
   PubMed Web of Science ®Google Scholar
• Friedrich DC, Genro JP, Sortica VA, et al. Distribution of CYP2D6 alleles and phenotypes in the Brazilian population. PLoS One. 2014;9:e110691.
   PubMed Web of Science ®Google Scholar
• Alsanosi SMM, Skiffington C, Padmanabhan S Pharmacokinetic pharmacogenomics. In: Handbook of pharmacogenomics and stratified medicine. Elsevier; 2014. p. 341–364.
   Google Scholar
• Suarez-Kurtz G. Pharmacogenomics in admixed populations: the Brazilian pharmacogenetics/pharmacogenomics network—REFARGEN. Pharmacogenomics J. 2004;4:347–348.
   PubMed Web of Science ®Google Scholar
• Karnes JH, Rettie AE, Somogyi AA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and HLA-B genotypes and phenytoin dosing: 2020 update. Clin Pharmacol Ther. 2021;109:302–309.
   PubMed Web of Science ®Google Scholar
• Awada Z, Zgheib NK. Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program. Pharmacogenomics. 2014;15(6):845–856.
   PubMed Web of Science ®Google Scholar
• Blankstein S. Pharmacogenomics: history, barriers, and regulatory solutions. Food Drug Law J. 2014;69(2):273–314.
   PubMed Web of Science ®Google Scholar
• Nishimura AA, Shirts BH, Salama J, et al. Physician perspectives of CYP2C19 and clopidogrel drug-gene interaction active clinical decision support alerts. Int J Med Inform. 2016;86:117–25.
   Web of Science ®Google Scholar
• Obara T, Abe S, Satoh M, et al. Awareness regarding clinical application of pharmacogenetics among Japanese pharmacists. Pharmgenomics Pers Med. 2015;8:35–41.
   PubMed Web of Science ®Google Scholar
• Santurro A, Vullo AM, Borro M, et al. Personalized medicine applied to forensic sciences: new advances and perspectives for a tailored forensic approach. Curr Pharm Biotechnol. 2017;18(3):263–273.
   Web of Science ®Google Scholar
• Dunnenberger HM, Crews KR, Hoffman JM, et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol. 2015;55:55.
   PubMed Web of Science ®Google Scholar